# Exelon Corp: financial statements, quarterly

EXC · Nasdaq · CIK 1109357 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/exc.md) · [Financials](/companies/exc/financials.md) · [Filings](/companies/exc/filings.md) · [Insiders](/companies/exc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/exc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,818](/filings/0001109357-24-000156.md) | [5,980](/filings/0001109357-24-000187.md) | [5,367 d](/filings/0001109357-26-000018.md) | [6,043](/filings/0001109357-25-000113.md) | [5,361](/filings/0001109357-25-000170.md) | [6,154](/filings/0001109357-25-000182.md) | [5,471 d](/filings/0001109357-26-000018.md) | [6,714](/filings/0001109357-26-000063.md) | [5,427](/filings/0001109357-25-000170.md) | [6,705](/filings/0001109357-25-000182.md) | [5,412 d](/filings/0001109357-26-000018.md) | [7,242](/filings/0001109357-26-000063.md) |
| Operating income | $m | [704](/filings/0001109357-24-000156.md) | [1,123](/filings/0001109357-24-000187.md) | [1,092 d](/filings/0001109357-26-000018.md) | [1,114](/filings/0001109357-25-000113.md) | [913](/filings/0001109357-25-000170.md) | [1,196](/filings/0001109357-25-000182.md) | [1,098 d](/filings/0001109357-26-000018.md) | [1,536](/filings/0001109357-26-000063.md) | [927](/filings/0001109357-25-000170.md) | [1,500](/filings/0001109357-25-000182.md) | [1,185 d](/filings/0001109357-26-000018.md) | [1,605](/filings/0001109357-26-000063.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [73.0](/filings/0001109357-24-000156.md) | [67.0](/filings/0001109357-24-000187.md) | [100 d](/filings/0001109357-26-000018.md) | [63.0](/filings/0001109357-25-000113.md) | [46.0](/filings/0001109357-25-000170.md) | [50.0](/filings/0001109357-25-000182.md) | [49.0 d](/filings/0001109357-26-000018.md) | [170](/filings/0001109357-26-000063.md) | [70.0](/filings/0001109357-25-000170.md) | [155](/filings/0001109357-25-000182.md) | [127 d](/filings/0001109357-26-000018.md) | [200](/filings/0001109357-26-000063.md) |
| Net income | $m | [343](/filings/0001109357-24-000187.md) | [700](/filings/0001109357-24-000187.md) | [617 d](/filings/0001109357-26-000018.md) | [658](/filings/0001109357-25-000182.md) | [448](/filings/0001109357-25-000182.md) | [707](/filings/0001109357-25-000182.md) | [647 d](/filings/0001109357-26-000018.md) | [908](/filings/0001109357-26-000063.md) | [391](/filings/0001109357-25-000182.md) | [875](/filings/0001109357-25-000182.md) | [594 d](/filings/0001109357-26-000018.md) | [919](/filings/0001109357-26-000063.md) |
| Diluted EPS | $ per share | [0.34](/filings/0001109357-24-000156.md) | [0.70](/filings/0001109357-24-000187.md) | not reported | [0.66](/filings/0001109357-25-000113.md) | [0.45](/filings/0001109357-25-000170.md) | [0.70](/filings/0001109357-25-000182.md) | not reported | [0.90](/filings/0001109357-26-000063.md) | [0.39](/filings/0001109357-25-000170.md) | [0.86](/filings/0001109357-25-000182.md) | not reported | [0.90](/filings/0001109357-26-000063.md) |
| Basic EPS | $ per share | [0.34](/filings/0001109357-24-000156.md) | [0.70](/filings/0001109357-24-000187.md) | not reported | [0.66](/filings/0001109357-25-000113.md) | [0.45](/filings/0001109357-25-000170.md) | [0.70](/filings/0001109357-25-000182.md) | not reported | [0.90](/filings/0001109357-26-000063.md) | [0.39](/filings/0001109357-25-000170.md) | [0.87](/filings/0001109357-25-000182.md) | not reported | [0.90](/filings/0001109357-26-000063.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.4](/filings/0001109357-24-000156.md) | [0.3](/filings/0001109357-24-000187.md) | [0.4](/filings/0001109357-26-000018.md) | [0.7](/filings/0001109357-25-000113.md) | [0.9](/filings/0001109357-25-000170.md) | [0.6](/filings/0001109357-25-000182.md) | [0.4](/filings/0001109357-26-000018.md) | [1.0](/filings/0001109357-25-000113.md) | [0.7](/filings/0001109357-25-000170.md) | [1.5](/filings/0001109357-25-000182.md) | [0.6](/filings/0001109357-26-000063.md) | [0.7](/filings/0001109357-26-000063.md) |
| Current assets | $bn | [7.5](/filings/0001109357-23-000067.md) | [7.5](/filings/0001109357-23-000097.md) | [8.1](/filings/0001109357-25-000043.md) | [8.2](/filings/0001109357-24-000120.md) | [8.6](/filings/0001109357-24-000156.md) | [8.0](/filings/0001109357-24-000187.md) | [8.4](/filings/0001109357-26-000018.md) | [8.8](/filings/0001109357-25-000113.md) | [8.7](/filings/0001109357-25-000170.md) | [9.2](/filings/0001109357-25-000182.md) | [9.5](/filings/0001109357-26-000063.md) | [9.0](/filings/0001109357-26-000063.md) |
| Total assets | $bn | [98.1](/filings/0001109357-23-000067.md) | [99.3](/filings/0001109357-23-000097.md) | [102](/filings/0001109357-25-000043.md) | [103](/filings/0001109357-24-000120.md) | [105](/filings/0001109357-24-000156.md) | [106](/filings/0001109357-24-000187.md) | [108](/filings/0001109357-26-000018.md) | [109](/filings/0001109357-25-000113.md) | [111](/filings/0001109357-25-000170.md) | [114](/filings/0001109357-25-000182.md) | [117](/filings/0001109357-26-000063.md) | [118](/filings/0001109357-26-000063.md) |
| Current liabilities | $bn | [7.9](/filings/0001109357-23-000067.md) | [8.8](/filings/0001109357-23-000097.md) | [9.9](/filings/0001109357-25-000043.md) | [8.0](/filings/0001109357-24-000120.md) | [8.3](/filings/0001109357-24-000156.md) | [7.4](/filings/0001109357-24-000187.md) | [9.6](/filings/0001109357-26-000018.md) | [8.1](/filings/0001109357-25-000113.md) | [9.2](/filings/0001109357-25-000170.md) | [9.8](/filings/0001109357-25-000182.md) | [10.3](/filings/0001109357-26-000063.md) | [9.6](/filings/0001109357-26-000063.md) |
| Total liabilities | $bn | [73.0](/filings/0001109357-23-000067.md) | [73.8](/filings/0001109357-23-000097.md) | [76.1](/filings/0001109357-25-000043.md) | [77.2](/filings/0001109357-24-000120.md) | [79.0](/filings/0001109357-24-000156.md) | [79.4](/filings/0001109357-24-000187.md) | [80.9](/filings/0001109357-26-000018.md) | [81.9](/filings/0001109357-25-000113.md) | [83.5](/filings/0001109357-25-000170.md) | [85.4](/filings/0001109357-25-000182.md) | [87.8](/filings/0001109357-26-000063.md) | [88.2](/filings/0001109357-26-000063.md) |
| Long-term debt | $bn | [39.5](/filings/0001109357-23-000067.md) | [39.4](/filings/0001109357-23-000097.md) | [39.7](/filings/0001109357-24-000187.md) | [42.3](/filings/0001109357-24-000120.md) | [43.0](/filings/0001109357-24-000156.md) | [43.7](/filings/0001109357-24-000187.md) | [42.9](/filings/0001109357-25-000182.md) | [45.3](/filings/0001109357-25-000113.md) | [45.5](/filings/0001109357-25-000170.md) | [46.3](/filings/0001109357-25-000182.md) | [47.4](/filings/0001109357-26-000063.md) | [47.9](/filings/0001109357-26-000063.md) |
| Current portion of debt | $bn | not reported | not reported | [1.4](/filings/0001109357-25-000043.md) | not reported | not reported | not reported | [1.5](/filings/0001109357-26-000018.md) | not reported | not reported | not reported | [1.7](/filings/0001109357-26-000018.md) | not reported |
| Short-term borrowings | $bn | [1.2](/filings/0001109357-23-000067.md) | [1.7](/filings/0001109357-23-000097.md) | [2.5](/filings/0001109357-25-000043.md) | [2.2](/filings/0001109357-24-000120.md) | [1.5](/filings/0001109357-24-000156.md) | [1.0](/filings/0001109357-24-000187.md) | [1.9](/filings/0001109357-26-000018.md) | [1.1](/filings/0001109357-25-000113.md) | [1.1](/filings/0001109357-25-000170.md) | [1.1](/filings/0001109357-25-000182.md) | [0.6](/filings/0001109357-26-000063.md) | [0.7](/filings/0001109357-26-000063.md) |
| Shareholders' equity | $bn | [25.1](/filings/0001109357-23-000067.md) | [25.5](/filings/0001109357-23-000097.md) | [25.8](/filings/0001109357-25-000043.md) | [26.1](/filings/0001109357-24-000120.md) | [26.2](/filings/0001109357-24-000156.md) | [26.6](/filings/0001109357-24-000187.md) | [26.9](/filings/0001109357-26-000018.md) | [27.6](/filings/0001109357-25-000113.md) | [27.6](/filings/0001109357-25-000170.md) | [28.1](/filings/0001109357-25-000182.md) | [28.8](/filings/0001109357-26-000063.md) | [29.3](/filings/0001109357-26-000063.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,277 d](/filings/0001109357-24-000156.md) | [1,531 d](/filings/0001109357-24-000187.md) | [1,411 d](/filings/0001109357-26-000018.md) | [992](/filings/0001109357-25-000113.md) | [1,462 d](/filings/0001109357-25-000170.md) | [1,689 d](/filings/0001109357-25-000182.md) | [1,426 d](/filings/0001109357-26-000018.md) | [1,200](/filings/0001109357-26-000063.md) | [1,511 d](/filings/0001109357-25-000170.md) | [2,299 d](/filings/0001109357-25-000182.md) | [1,244 d](/filings/0001109357-26-000018.md) | [1,724](/filings/0001109357-26-000063.md) |
| Capital expenditure | $m | [1,804 d](/filings/0001109357-24-000156.md) | [1,855 d](/filings/0001109357-24-000187.md) | [1,868 d](/filings/0001109357-26-000018.md) | [1,767](/filings/0001109357-25-000113.md) | [1,699 d](/filings/0001109357-25-000170.md) | [1,695 d](/filings/0001109357-25-000182.md) | [1,936 d](/filings/0001109357-26-000018.md) | [1,946](/filings/0001109357-26-000063.md) | [2,013 d](/filings/0001109357-25-000170.md) | [2,136 d](/filings/0001109357-25-000182.md) | [2,434 d](/filings/0001109357-26-000018.md) | [2,358](/filings/0001109357-26-000063.md) |
| Dividends paid | $m | [359 d](/filings/0001109357-24-000156.md) | [357 d](/filings/0001109357-24-000187.md) | [359 d](/filings/0001109357-26-000018.md) | [381](/filings/0001109357-25-000113.md) | [380 d](/filings/0001109357-25-000170.md) | [381 d](/filings/0001109357-25-000182.md) | [382 d](/filings/0001109357-26-000018.md) | [403](/filings/0001109357-26-000063.md) | [405 d](/filings/0001109357-25-000170.md) | [404 d](/filings/0001109357-25-000182.md) | [405 d](/filings/0001109357-26-000018.md) | [430](/filings/0001109357-26-000063.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [982](/filings/0001109357-23-000067.md) | [989](/filings/0001109357-23-000097.md) | [996](/filings/0001109357-24-000120.md) | [996](/filings/0001109357-24-000156.md) | [997](/filings/0001109357-24-000187.md) | [1,001](/filings/0001109357-25-000113.md) | [1,001](/filings/0001109357-25-000170.md) | [1,004](/filings/0001109357-25-000182.md) | [1,009](/filings/0001109357-26-000063.md) | [1,012](/filings/0001109357-25-000170.md) | [1,013](/filings/0001109357-25-000182.md) | [1,026](/filings/0001109357-26-000063.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,023,208,142 at 2026-03-31, from the cover of the [10-Q filed 2026-05-06](/filings/0001109357-26-000063.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.